白细胞介素-6 抑制剂在治疗 COVID-19 相关细胞因子释放综合征中的作用。
Role of IL-6 inhibitor in treatment of COVID-19-related cytokine release syndrome.
机构信息
Clinical Laboratory of Emergency Medicine, Tianjin Union Medical Centre, Tianjin, China.
Graduate School of Tianjin Medical University, Tianjin, China.
出版信息
Int J Med Sci. 2021 Jan 21;18(6):1356-1362. doi: 10.7150/ijms.53564. eCollection 2021.
Abstract
Cytokine release syndrome (CRS) may be the key factor in the pathology of severe coronavirus disease 2019 (COVID-19). As a major driver in triggering CRS in patients with COVID-19, interleukin-6 (IL-6) appears to be a promising target for therapeutics. The results of inhibiting both trans- and classical- signaling with marketed IL-6 inhibitors (tocilizumab, siltuximab and sarilumab) in severe COVID-19 patients are effective based on several small studies and case reports thus far. In this review, we described the evidence of the IL-6 response in patients with COVID-19, clarified the pathogenesis of the role of IL-6-mediated CRS in severe COVID-19, and highlighted the rationale for the use of anti-IL-6 agents and key information regarding the potential features of these IL-6 inhibitors in COVID-19 patients.
摘要
细胞因子释放综合征（CRS）可能是严重 2019 冠状病毒病（COVID-19）病理学的关键因素。白细胞介素-6（IL-6）作为引发 COVID-19 患者 CRS 的主要驱动因素，似乎是治疗的一个有前途的靶点。迄今为止，几项小型研究和病例报告表明，用市售的 IL-6 抑制剂（托珠单抗、西妥昔单抗和沙利鲁单抗）抑制转导和经典信号对重症 COVID-19 患者有效。在这篇综述中，我们描述了 COVID-19 患者中 IL-6 反应的证据，阐明了 IL-6 介导的 CRS 在严重 COVID-19 中的发病机制，并强调了使用抗 IL-6 药物的基本原理以及这些 IL-6 抑制剂在 COVID-19 患者中的潜在特征的关键信息。
相似文献
1
Role of IL-6 inhibitor in treatment of COVID-19-related cytokine release syndrome.白细胞介素-6 抑制剂在治疗 COVID-19 相关细胞因子释放综合征中的作用。
Int J Med Sci. 2021 Jan 21;18(6):1356-1362. doi: 10.7150/ijms.53564. eCollection 2021.
2
Overview on the use of IL-6 agents in the treatment of patients with cytokine release syndrome (CRS) and pneumonitis related to COVID-19 disease.关于白细胞介素 6 制剂在治疗与 COVID-19 疾病相关的细胞因子释放综合征（CRS）和肺炎中的应用概述。
Expert Opin Investig Drugs. 2020 Dec;29(12):1407-1412. doi: 10.1080/13543784.2020.1840549. Epub 2020 Dec 1.
3
IL-6 trans-signaling induces plasminogen activator inhibitor-1 from vascular endothelial cells in cytokine release syndrome.白细胞介素-6 转导信号诱导细胞因子释放综合征中的血管内皮细胞产生纤溶酶原激活物抑制剂-1。
Proc Natl Acad Sci U S A. 2020 Sep 8;117(36):22351-22356. doi: 10.1073/pnas.2010229117. Epub 2020 Aug 21.
4
IL-6 Blockade in Cytokine Storm Syndromes.白细胞介素-6 阻断在细胞因子风暴综合征中的应用。
Adv Exp Med Biol. 2024;1448:565-572. doi: 10.1007/978-3-031-59815-9_37.
5
Is IL-6 a key cytokine target for therapy in COVID-19?白细胞介素-6 是 COVID-19 治疗的关键细胞因子靶点吗？
Nat Rev Immunol. 2021 Jun;21(6):337-339. doi: 10.1038/s41577-021-00553-8.
6
Clinical outcomes in COVID-19 patients treated with tocilizumab: An individual patient data systematic review.托珠单抗治疗 COVID-19 患者的临床结局：一项个体患者数据系统评价。
J Med Virol. 2020 Nov;92(11):2516-2522. doi: 10.1002/jmv.26038. Epub 2020 Jun 9.
7
The Role of Tocilizumab in Cytokine Storm and Improving Outcomes in COVID-19.托珠单抗在细胞因子风暴及改善 COVID-19 结局中的作用。
Recent Pat Antiinfect Drug Discov. 2020;15(2):104-112. doi: 10.2174/1574891X15666200922155712.
8
Therapeutic Role of Tocilizumab in SARS-CoV-2-Induced Cytokine Storm: Rationale and Current Evidence.托珠单抗在 SARS-CoV-2 诱导的细胞因子风暴中的治疗作用：原理和现有证据。
Int J Mol Sci. 2021 Mar 17;22(6):3059. doi: 10.3390/ijms22063059.
9
Treatment of severely ill COVID-19 patients with anti-interleukin drugs (COV-AID): A structured summary of a study protocol for a randomised controlled trial.抗白细胞介素药物治疗重症 COVID-19 患者（COV-AID）：一项随机对照试验研究方案的结构化总结。
Trials. 2020 Jun 3;21(1):468. doi: 10.1186/s13063-020-04453-5.
10
Sarilumab (IL-6R antagonist) in critically ill patients with cytokine release syndrome by SARS-CoV2.沙利鲁单抗（IL-6R 拮抗剂）治疗 SARS-CoV2 引起的细胞因子释放综合征的危重症患者。
Medicine (Baltimore). 2021 May 14;100(19):e25923. doi: 10.1097/MD.0000000000025923.
引用本文的文献
1
Abatacept, Golimumab, and Sarilumab as Selected Bio-Originator Disease-Modifying Antirheumatic Drugs with Diverse Mechanisms of Action in Their Current Use in Treatment.阿巴西普、戈利木单抗和托珠单抗作为当前治疗中具有不同作用机制的选定生物原研改善病情抗风湿药。
J Clin Med. 2025 Mar 19;14(6):2107. doi: 10.3390/jcm14062107.
2
Cytokine Storm in COVID-19: Exploring IL-6 Signaling and Cytokine-Microbiome Interactions as Emerging Therapeutic Approaches.COVID-19 中的细胞因子风暴：探索 IL-6 信号和细胞因子-微生物组相互作用作为新兴治疗方法。
Int J Mol Sci. 2024 Oct 24;25(21):11411. doi: 10.3390/ijms252111411.
3
Plausible mechanism of drug resistance and side-effects of COVID-19 therapeutics: a bottleneck for its eradication.新冠病毒治疗药物耐药性和副作用的可能机制：其根除的瓶颈。
Daru. 2024 Dec;32(2):801-823. doi: 10.1007/s40199-024-00524-z. Epub 2024 Jul 19.
4
The Potential Mechanisms of Arrhythmia in Coronavirus disease-2019.新型冠状病毒 2019 型心律失常的潜在机制。
Int J Med Sci. 2024 May 19;21(7):1366-1377. doi: 10.7150/ijms.94578. eCollection 2024.
5
Adverse drug reactions associated with COVID-19 management.与 COVID-19 管理相关的药物不良反应。
Naunyn Schmiedebergs Arch Pharmacol. 2024 Oct;397(10):7353-7376. doi: 10.1007/s00210-024-03137-0. Epub 2024 May 14.
6
Impacts of Inflammatory Cytokines Variants on Systemic Inflammatory Profile and COVID-19 Severity.炎症细胞因子变体对全身炎症谱及新冠病毒疾病严重程度的影响
J Epidemiol Glob Health. 2024 Jun;14(2):363-378. doi: 10.1007/s44197-024-00204-w. Epub 2024 Feb 20.
7
Unveiling COVID-19 Secrets: Harnessing Cytokines as Powerful Biomarkers for Diagnosis and Predicting Severity.揭开新冠病毒的秘密：利用细胞因子作为诊断和预测严重程度的强大生物标志物
J Inflamm Res. 2023 Dec 11;16:6055-6070. doi: 10.2147/JIR.S439217. eCollection 2023.
8
Dipeptidyl-peptidase 3 and IL-6: potential biomarkers for diagnostics in COVID-19 and association with pulmonary infiltrates.二肽基肽酶 3 和白细胞介素 6：COVID-19 诊断的潜在生物标志物，与肺部浸润有关。
Clin Exp Med. 2023 Dec;23(8):4919-4935. doi: 10.1007/s10238-023-01193-z. Epub 2023 Sep 21.
9
The Important Role of Interleukin-2 in COVID-19.白细胞介素-2 在 COVID-19 中的重要作用。
J Immunol Res. 2023 Aug 22;2023:7097329. doi: 10.1155/2023/7097329. eCollection 2023.
10
Treatment of cytokine release syndrome-induced vascular endothelial injury using mesenchymal stem cells.间充质干细胞治疗细胞因子释放综合征引起的血管内皮损伤。
Mol Cell Biochem. 2024 May;479(5):1149-1164. doi: 10.1007/s11010-023-04785-1. Epub 2023 Jul 1.
本文引用的文献
1
Interleukin-6 receptor blocking with intravenous tocilizumab in COVID-19 severe acute respiratory distress syndrome: A retrospective case-control survival analysis of 128 patients.COVID-19 严重急性呼吸窘迫综合征中静脉注射托珠单抗阻断白细胞介素-6 受体：128 例患者回顾性病例对照生存分析。
J Autoimmun. 2020 Nov;114:102511. doi: 10.1016/j.jaut.2020.102511. Epub 2020 Jul 8.
2
Potential Role of Anti-interleukin (IL)-6 Drugs in the Treatment of COVID-19: Rationale, Clinical Evidence and Risks.抗白细胞介素 (IL)-6 药物在 COVID-19 治疗中的潜在作用：原理、临床证据和风险。
BioDrugs. 2020 Aug;34(4):415-422. doi: 10.1007/s40259-020-00430-1.
3
COVID-19 pneumonia treated with Sarilumab: A clinical series of eight patients.用萨瑞鲁单抗治疗的新型冠状病毒肺炎：8例患者的临床系列报道
J Med Virol. 2020 Nov;92(11):2368-2370. doi: 10.1002/jmv.26062. Epub 2020 Jun 16.
4
Elevated interleukin-6 is associated with severity of COVID-19: A meta-analysis.白细胞介素-6升高与新型冠状病毒肺炎严重程度相关：一项荟萃分析。
J Med Virol. 2021 Jan;93(1):35-37. doi: 10.1002/jmv.26085. Epub 2020 Oct 30.
5
COVID-19 and the immune system.COVID-19 与免疫系统。
Physiol Res. 2020 Jul 16;69(3):379-388. doi: 10.33549/physiolres.934492. Epub 2020 May 29.
6
Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: A single center study of 100 patients in Brescia, Italy.托珠单抗治疗伴有炎症过度反应和急性呼吸衰竭的重症 COVID-19 肺炎：意大利布雷西亚单中心 100 例患者研究。
Autoimmun Rev. 2020 Jul;19(7):102568. doi: 10.1016/j.autrev.2020.102568. Epub 2020 May 3.
7
Pilot prospective open, single-arm multicentre study on off-label use of tocilizumab in patients with severe COVID-19.一项关于托珠单抗在重症 COVID-19 患者中的超适应证使用的前瞻性开放、单臂多中心研究。
Clin Exp Rheumatol. 2020 May-Jun;38(3):529-532. Epub 2020 May 1.
8
Effective treatment of severe COVID-19 patients with tocilizumab.托珠单抗治疗重症 COVID-19 患者有效。
Proc Natl Acad Sci U S A. 2020 May 19;117(20):10970-10975. doi: 10.1073/pnas.2005615117. Epub 2020 Apr 29.
9
Use of Tocilizumab for COVID-19-Induced Cytokine Release Syndrome: A Cautionary Case Report.托珠单抗治疗 COVID-19 相关细胞因子释放综合征：一例警示性病例报告。
Chest. 2020 Jul;158(1):e15-e19. doi: 10.1016/j.chest.2020.04.024. Epub 2020 Apr 25.
10
Macrophages: a Trojan horse in COVID-19?巨噬细胞：新冠病毒肺炎中的特洛伊木马？
Nat Rev Immunol. 2020 Jun;20(6):351. doi: 10.1038/s41577-020-0317-2.
Zotero 插件